J.E.\S. support the use of the approved pembrolizumab dose of 2 mg/kg every 3 weeks without dose adjustment in a variety of patient subpopulations. Study Highlights WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC? ? Pembrolizumab is a potent antibody against the cellular immune switch PD\1 receptor with high activity […]
Daily Archives: July 1, 2022
1 post